Fig. 6. High expression of CDKN1C mRNA in the bone marrow of patients with MDS coincides with a better response to 5-azacytidine plus entinostat.

a RT-qPCR analysis of ZBTB38 and b CDKN1C mRNA expression in bone marrow samples from patients with MDS, AML with myelodysplasia-related changes (AML-MRC) and de novo AML. MDS patients were grouped into lower and higher-risk categories according to the Revised International Prognostic Scoring System. c Kaplan–Meier plots of overall survival in MDS patients classed according to low and high ZBTB38 (left panel) or CDKN1C (right panel) mRNA expression levels. d Expression of ZBTB38, RBBP6, USP9X, and CDKN1C in samples from patients with MDS before azacytidine and entinostat treatment (D0) and 15 days later (D15). Responders to the therapy are highlighted in orange; non responder are presented in grey (data from ref. ¹). Significant difference between responder and non-responder at Day 0 is indicated by a P-value in the graph